|
EDIT | Editas Medicine, Inc. |
|
|
EDIT | Editas Medicine, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.44 |
| Leverage | 55.65% |
| Market Cap | $ 240.5m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -73.9m |
| Margin | -158.41% |
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.